Recent developments in anti-rheumatic drugs in pediatrics treatment of juvenile idiopathic arthritis 英文参考文献.docVIP

Available online /content/11/1/216 Review Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis Kristen Hayward and Carol A Wallace Division of Rheumatology, University of Washington School of Medicine, Seattle Children’s Hospital, 4800 Sandpoint Way, NE MS R-5420, Seattle, WA 98105, USA Corresponding author: Carol A Wallace, cwallace@ Published: 23 February 2009 Arthritis Research Therapy 2009, 11:216 (doi:10.1186/ar2619) This article is online at /content/11/1/216 ? 2009 BioMed Central Ltd Abstract chronic uveitis associated with JIA) [3,4]. In the case of the systemic-onset form of JIA (SOJIA), untreated disease may even result in multiple organ failure and death. Juvenile idiopathic arthritis (JIA) is the most common autoimmune– autoinflammatory disease in childhood and affects approximately 1 in 1,000 children. Despite advances in diagnosis and treatment options, JIA remains a chronic condition for most affected children. Recent evidence suggests that disease control at onset may determine the tempo of subsequent disease course and long-term outcomes, and raises the concept of a therapeutic window of opportunity in patients with JIA. This underscores the importance of early aggressive treatment in patients with JIA. With the advent of novel biologic therapeutics, the repertoire of agents available for treatment of children with JIA has greatly increased. The present article will summarize recent developments in the medical treatment of children with JIA and will offer insights into emerging therapies. Twenty years ago it was commonly believed that childhood- onset arthritis might subside in adulthood. Recent studies, however, have demonstrated that sustained resolution of disease occurs in only a small minority of JIA patients (as many as 50% of children with JIA enter adulthood with on- going, active disea